NASDAQ:DBVT DBV Technologies - DBVT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. $1.61 -0.03 (-1.83%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.60▼$1.6850-Day Range$1.28▼$1.7352-Week Range$1.08▼$3.43Volume19,545 shsAverage Volume100,640 shsMarket Capitalization$303.12 millionP/E RatioN/ADividend YieldN/APrice Target$5.38 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media DBV Technologies MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside233.9% Upside$5.38 Price TargetShort InterestHealthy0.96% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.97) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.63 out of 5 starsMedical Sector855th out of 986 stocksBiological Products, Except Diagnostic Industry149th out of 165 stocks 3.3 Analyst's Opinion Consensus RatingDBV Technologies has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.38, DBV Technologies has a forecasted upside of 233.9% from its current price of $1.61.Amount of Analyst CoverageDBV Technologies has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.96% of the outstanding shares of DBV Technologies have been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in DBV Technologies has recently decreased by 1.63%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDBV Technologies does not currently pay a dividend.Dividend GrowthDBV Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DBVT. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for DBV Technologies this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added DBV Technologies to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DBV Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.60% of the stock of DBV Technologies is held by insiders.Percentage Held by InstitutionsOnly 18.37% of the stock of DBV Technologies is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DBV Technologies are expected to grow in the coming year, from ($0.97) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV Technologies is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV Technologies is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV Technologies has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DBV Technologies (NASDAQ:DBVT) StockDBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.Read More Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DBVT Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comDBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.comMarch 19, 2023 | americanbankingnews.comBrokerages Set DBV Technologies S.A. (NASDAQ:DBVT) Target Price at $6.67March 23, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 15, 2023 | americanbankingnews.comDBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.comMarch 13, 2023 | finance.yahoo.comDBV Technologies UpdateMarch 7, 2023 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 - 7 Years OldMarch 7, 2023 | finance.yahoo.comDBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years OldMarch 7, 2023 | finance.yahoo.comDBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years OldMarch 23, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 4, 2023 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration DocumentMarch 4, 2023 | benzinga.comDBV Technologies Stock (NASDAQ:DBVT), Guidance and ForecastMarch 3, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: DBV Technologies SA – American (DBVT), Veru (VERU)March 3, 2023 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies Reports Full Year 2022 Financial Results and Business UpdateMarch 3, 2023 | msn.comDBV Technologies GAAP EPS of -$1.24, revenue of $4.8MMarch 3, 2023 | finance.yahoo.comDBV Technologies Reports Full Year 2022 Financial Results and Business UpdateMarch 3, 2023 | finance.yahoo.comDBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration DocumentMarch 1, 2023 | benzinga.comEarnings Preview: DBV TechnologiesMarch 1, 2023 | benzinga.comEarnings Preview: DBV TechnologiesFebruary 27, 2023 | finance.yahoo.comDBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023February 23, 2023 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies to Participate in Upcoming AAAAI 2023 CongressFebruary 21, 2023 | finance.yahoo.comDBV Technologies to Participate in Upcoming AAAAI 2023 CongressJanuary 4, 2023 | finance.yahoo.comMonthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022December 24, 2022 | ca.finance.yahoo.comDBV Technologies S.A. (DBVT)December 23, 2022 | finance.yahoo.comDBV Technologies Shares Jumps As FDA Lifts Partial Hold On Pivotal Trial For Peanut Allergy PatchDecember 23, 2022 | msn.comWhy DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving PremarketDecember 23, 2022 | seekingalpha.comDBV stock soars 30% as FDA lifts partial hold on phase 3 trial of peanut allergy patchDecember 23, 2022 | finance.yahoo.comDBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal TrialSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DBVT Company Calendar Last Earnings8/01/2021Today3/23/2023Next Earnings (Estimated)5/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DBVT CUSIPN/A CIK1613780 Webwww.dbv-technologies.com Phone(315) 542-7878Fax33-1-43-26-10-83Employees92Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.38 High Stock Price Forecast$10.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+235.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,270,000.00 Net Margins-778.60% Pretax Margin-777.38% Return on Equity-52.54% Return on Assets-42.92% Debt Debt-to-Equity RatioN/A Current Ratio7.56 Quick Ratio7.56 Sales & Book Value Annual Sales$4.84 million Price / Sales62.24 Cash FlowN/A Price / Cash FlowN/A Book Value$1.03 per share Price / Book1.55Miscellaneous Outstanding Shares188,274,000Free Float187,144,000Market Cap$301.24 million OptionableOptionable Beta1.23 Key ExecutivesDaniel TasséChief Executive Officer & Executive DirectorSébastien RobitailleChief Financial OfficerPharis MohideenChief Medical OfficerPascal WotlingChief Technical Operations & Quality OfficerPascale EhouarnChief Engineering, Manufacturing & Supply OfficerKey CompetitorsHumacyteNASDAQ:HUMAVoyager TherapeuticsNASDAQ:VYGRSangamo TherapeuticsNASDAQ:SGMOTarsus PharmaceuticalsNASDAQ:TARSAutolus TherapeuticsNASDAQ:AUTLView All CompetitorsInstitutional OwnershipBraidwell LPBought 12,107,785 shares on 2/15/2023Ownership: 6.431%Millennium Management LLCBought 305,562 shares on 2/15/2023Ownership: 0.463%Morgan StanleySold 35,921 shares on 2/15/2023Ownership: 0.263%Jane Street Group LLCBought 35,010 shares on 2/15/2023Ownership: 0.019%Boxer Capital LLCSold 684,598 shares on 2/14/2023Ownership: 0.770%View All Institutional Transactions DBVT Stock - Frequently Asked Questions Should I buy or sell DBV Technologies stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DBVT shares. View DBVT analyst ratings or view top-rated stocks. What is DBV Technologies' stock price forecast for 2023? 5 equities research analysts have issued 1 year price targets for DBV Technologies' stock. Their DBVT share price forecasts range from $1.50 to $10.00. On average, they predict the company's stock price to reach $5.38 in the next year. This suggests a possible upside of 235.9% from the stock's current price. View analysts price targets for DBVT or view top-rated stocks among Wall Street analysts. How have DBVT shares performed in 2023? DBV Technologies' stock was trading at $1.53 at the beginning of 2023. Since then, DBVT shares have increased by 4.6% and is now trading at $1.60. View the best growth stocks for 2023 here. When is DBV Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023. View our DBVT earnings forecast. How were DBV Technologies' earnings last quarter? DBV Technologies S.A. (NASDAQ:DBVT) posted its earnings results on Sunday, August, 1st. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.36. The business earned ($1.49) million during the quarter, compared to the consensus estimate of $3.53 million. DBV Technologies had a negative trailing twelve-month return on equity of 52.54% and a negative net margin of 778.60%. What other stocks do shareholders of DBV Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO). What is DBV Technologies' stock symbol? DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT." Who are DBV Technologies' major shareholders? DBV Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Braidwell LP (6.43%), VR Adviser LLC (4.94%), RA Capital Management L.P. (1.04%), Boxer Capital LLC (0.77%), Millennium Management LLC (0.46%) and Morgan Stanley (0.26%). How do I buy shares of DBV Technologies? Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DBV Technologies' stock price today? One share of DBVT stock can currently be purchased for approximately $1.60. How much money does DBV Technologies make? DBV Technologies (NASDAQ:DBVT) has a market capitalization of $301.24 million and generates $4.84 million in revenue each year. The company earns $-96,270,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. How can I contact DBV Technologies? DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The official website for the company is www.dbv-technologies.com. The company can be reached via phone at (315) 542-7878, via email at sara.sherman@dbv-technologies.com, or via fax at 33-1-43-26-10-83. This page (NASDAQ:DBVT) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.